Want to see CH:BANB full AI Analyst Report?
BANB Stock Chart & Stats
CHF75.75
-CHF1.90(-2.53%)
At close: 4:00 PM EDT
CHF75.75
-CHF1.90(-2.53%)
Day’s Range― - ―
52-Week RangeCHF48.52 - CHF86.00
Previous CloseN/A
Volume86.94K
Average Volume (3M)91.00K
Market Cap
CHF6.45B
Enterprise ValueCHF5.83B
Total Cash (Recent Filing)CHF51.57M
Total Debt (Recent Filing)CHF208.10M
Price to Earnings (P/E)42.3
Beta0.77
Next Earnings
Mar 04, 2027EPS Estimate
1.58Next Dividend Ex-DateN/A
Dividend Yield1.07%
Share Statistics
EPS (TTM)1.99
Shares Outstanding75,000,000
10 Day Avg. Volume87,663
30 Day Avg. Volume91,004
Financial Highlights & Ratios
PEG Ratio1.27
Price to Book (P/B)3.08
Price to Sales (P/S)6.46
P/FCF Ratio-93.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF83.60Price Target Upside10.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)2.4
Revenue Forecast (FY)CHF942.18M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageThe exceptionally conservative capital structure reduces financial strain and preserves flexibility for capacity investment, customer programs, or downturns. A large and growing equity base also supports resilience because profitability is not dependent on heavy borrowing or leverage.
Resilient Profitability And Revenue GrowthSteady multi-year revenue expansion and solid profitability indicate durable demand for Bachem’s peptide and oligonucleotide manufacturing capabilities. This earnings base can support continued investment and customer support while providing operating resilience across development and commercial projects.
Specialized Peptide And Oligonucleotide CDMO PositionBachem’s specialized CDMO model serves customers across drug discovery, clinical development, and commercial-scale production. Supporting complex, regulated therapeutics can deepen customer relationships and create opportunities for recurring manufacturing demand as successful programs advance.
Bears Say
Persistent Negative Free Cash FlowRepeated negative free cash flow means substantial investment spending or working-capital needs are absorbing internally generated cash. If this pattern persists, Bachem may have less flexibility to fund expansion, dividends, or other strategic priorities without relying on external financing.
Gradual Margin CompressionAlthough current margins remain healthy, the downward trend suggests that cost growth, business mix, or investment requirements are taking a larger share of revenue. Continued compression could reduce the earnings benefit of future sales growth and weaken operating leverage over time.
Recent Debt IncreaseThe 2025 increase in total debt is notable against Bachem’s previously near-zero leverage profile. While leverage remains very low, a continued buildup would gradually reduce balance-sheet conservatism and could add financing costs or constrain future capital allocation.
Bachem Holding AG News
BANB FAQ
What was Bachem Holding AG Class B’s price range in the past 12 months?
Bachem Holding AG Class B lowest stock price was CHF48.52 and its highest was CHF86.00 in the past 12 months.
What is Bachem Holding AG Class B’s market cap?
Bachem Holding AG Class B’s market cap is CHF6.45B.
When is Bachem Holding AG Class B’s upcoming earnings report date?
Bachem Holding AG Class B’s upcoming earnings report date is Mar 04, 2027 which is in 132 days.
How were Bachem Holding AG Class B’s earnings last quarter?
Bachem Holding AG Class B released its earnings results on Jul 30, 2026. The company reported CHF0.67 earnings per share for the quarter, beating the consensus estimate of CHF0.468 by CHF0.202.
Is Bachem Holding AG Class B overvalued?
According to Wall Street analysts Bachem Holding AG Class B’s price is currently Undervalued.
Does Bachem Holding AG Class B pay dividends?
Bachem Holding AG Class B pays a Annually dividend of CHF0.9 which represents an annual dividend yield of 1.07%. See more information on Bachem Holding AG Class B dividends here
What is Bachem Holding AG Class B’s EPS estimate?
Bachem Holding AG Class B’s EPS estimate is 1.58.
How many shares outstanding does Bachem Holding AG Class B have?
Bachem Holding AG Class B has 75,000,000 shares outstanding.
What happened to Bachem Holding AG Class B’s price movement after its last earnings report?
Bachem Holding AG Class B reported an EPS of CHF0.67 in its last earnings report, beating expectations of CHF0.468. Following the earnings report the stock price went up 4.62%.
Which hedge fund is a major shareholder of Bachem Holding AG Class B?
Currently, no hedge funds are holding shares in CH:BANB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bachem Holding AG Class B
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
BANB Stock 12 Month Forecast
Average Price Target
CHF83.60
▲(10.36% Upside)